# About Wolverine Safe: An Independent BPC-157 TB-500 Literature Digest > Wolverine Safe is an independent editorial project summarizing the peer-reviewed research on the BPC-157 TB-500 blend, with its safety record kept in view. Not a clinic, not a vendor. Wolverine Safe is an independent editorial digest of the published research on the BPC-157 TB-500 blend. It is a reading instrument, not a medical service — a studio that shows the record straight. ## What this site is Wolverine Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The site is built as a studio safety brief — each peptide set down on its own plinth, shown accurately under even light, with the gaps and the one flagged safety signal kept in plain view rather than airbrushed out. That format is a deliberate editorial choice. The BPC-157 TB-500 literature has a conspicuous shape: strong single-compound preclinical evidence for each peptide, no controlled combination study, and a real Thymosin Beta-4 tumor/angiogenesis safety signal. A brief that renders each finding as a sober readout, and renders the missing combination data as a gap rather than a result, makes that shape impossible to skim past. ## What 'safe' means here The word "safe" in this site's name is editorial framing, not a verdict on the blend. It does not assert that the blend is safe — this brief is explicit that long-term human safety is unknown for both constituents [8][9]. It marks the register this publisher works in: the sober studio that shows the safety record straight, flags the Thymosin Beta-4 tumor/angiogenesis signal honestly, and reports the mixed and null results alongside the favorable ones. We do not offer treatment, consultation, prescription, or any clinical service. We claim no physical address, no phone line, and no clinical staff. There are no "our doctors," no "our pharmacists," and no clinical team behind this page; there is an editorial process that reads published studies and FDA sources and summarizes them with citations. When a page here describes a dose, it describes the dose administered to a specific species in a specific study — never a recommendation for any person. ## How the record is kept Every quantitative claim on this site is tied to a numbered source in [the full reference list](/references). The mechanism and efficacy findings come from the peer-reviewed literature; the evidence-quality framing comes from recent systematic and narrative reviews [8][9][10]; the regulatory facts on [Wolverine legal status and 503A compounding](/legal-status) cite FDA pages directly. Where the evidence is strong, this site says so plainly — BPC-157's transected-Achilles tendon repair [1] and VEGFR2-Akt-eNOS angiogenesis [2], and Thymosin Beta-4's 1:1 actin sequestration [3], are real, reproducible preclinical findings. Where the evidence is absent or cuts the other way — no controlled combination study, no validated blend dose, no human combination safety data, an mdx result that gained fibers but not function — this site says that too [4][8]. The discipline is the same one a studio applies to a product: show it accurately, and do not retouch the flaws out of the frame. --- Two peptides set on one studio table and shown straight — BPC-157 and TB-500 lit specimen by specimen, the Thymosin Beta-4 tumor signal and the 503A status left in plain view, with no clinic behind the lens and nothing here dispensed.